Phase 2 Study of the ТВ/Flu-05Е Tuberculosis Vaccine

NCT ID: NCT06873282

Last Updated: 2025-03-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 160 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-13
• Study Completion Date: 2024-04-11

Brief Summary

The aim of the study is to investigate immunogenicity and safety of the TB/Flu-05E single-dose intranasal vaccine for the prevention of Tuberculosis infection in BCG-vaccinated Volunteers aged 18-50 years

Detailed Description

Study includes 160 participants aged 18 to 50, randomized at 3:1 ratio, to receive single intranasal dose of TB/Flu-05E vaccine or placebo, correspondingly. Duration of the study for each participant is about 4 months (no more than 114 days).

Conditions

Tuberculosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

TB/Flu-05E

Single dose of TB/Flu-05E vector vaccine

Group Type: EXPERIMENTAL

TB/Flu-05E

Intervention Type: BIOLOGICAL

Participants will receive single intranasal injection of TB/Flu-05E vaccine in 0.5 ml, containing 7.7 lg EID50 of A/H1N1pdm09 recombinant attenuated influenza vector with modified NS gene, encoding for the TB10.4 and HspX antigens of M. tuberculosis

Placebo

Single dose of Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Participants will receive single intranasal injection of physiological buffer in 0.5 ml

Interventions

TB/Flu-05E

Participants will receive single intranasal injection of TB/Flu-05E vaccine in 0.5 ml, containing 7.7 lg EID50 of A/H1N1pdm09 recombinant attenuated influenza vector with modified NS gene, encoding for the TB10.4 and HspX antigens of M. tuberculosis

Intervention Type: BIOLOGICAL

Placebo

Participants will receive single intranasal injection of physiological buffer in 0.5 ml

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Healthy BCG-vaccinated men and women aged 18 to 50 years

2. Availability of signed informed consent

3. Diagnosed "healthy" according to the data of standard clinical, laboratory and instrumental examination methods, with the absence of clinically significant changes. Participants with chronic conditions that do not require special treatment, such as diabetes mellitus, hypertension, or heart disease, are eligible to participate in this study if the investigator considers the participant's condition to be medically stable

4. The ability and willingness to make entries in the diary of self-observation, as well as to carry out all the visits foreseen in the study for control medical observation

5. Consent of study participants to use effective contraceptive methods throughout their participation in the study. In this study, volunteers can use the following methods of contraception:

• Barrier methods:

• male condom and spermicide
• cervical cap and spermicide
• vaginal diaphragm and spermicide
• Intrauterine device
• Hormonal intrauterine device
• Hormonal contraceptives:

• hormonal implants
• hormone injections
• combined oral contraceptives
• mini-pill
• contraceptive patch
• Abstinence from sexual activity.

6. Body weight ≥ 50 kg

7. Negative test for alcohol in exhaled air

8. Values of the complete blood count and biochemical blood analysis (during the screening) within 0.9*reference range lower limit and 1,1 * reference range upper limit

9. Negative tests for HIV, hepatitis B, hepatitis C, and syphilis

10. Absence of pathological changes on the chest X-ray (fluorogram of the lungs).

Exclusion Criteria

1. Participation in another clinical study within three months prior to the start of the current study; planning to participate in another study during the current study period

2. Clinical, radiological or laboratory signs of active or previously transferred tuberculosis of any localization.

3. Existence in the past or present of contact with patients with any form of tuberculosis (at home, at work, in the circle of friends and acquaintances)

4. Tuberculous infection confirmed by the TB-FERON IGRA laboratory test

5. Immunization with BCG within six months prior to enrollment in the current study

6. Contact with COVID-19 patients within 14 days prior to the start of the clinical study

7. Positive rapid test result for SARS-CoV-2 antigen

8. Immunization with any other non-study vaccine product within three weeks prior to enrollment in the current study, or refusal to postpone such until the end of the three-week period after completion of the current study

9. Regular use of nasal irrigation therapy during the last six months prior to enrollment in the current study or episodic use of the above method of treatment in the two weeks prior to the screening

10. History of frequent nosebleeds (>5) during the year prior to the current study

11. Features of the nasal anatomy that may complicate intranasal administration of the study drug.

12. Surgical interventions or traumatic injuries in the sinus area, paranasal sinuses, or traumatic injuries of the nose within a month before screening

13. Symptoms of acute respiratory disease, including fever, or other acute illness at the time of screening or within two weeks prior to screening

14. Treatment with immunoglobulins or other blood derived medications in the three months prior to screening or planning such treatment during the period of participation in the current study

15. History of bronchial asthma

16. Hypersensitivity and the presence of severe allergic reactions, including Quincke's edema, anaphylactic shock after the previous administration of any vaccine

17. History of wheezing after previous immunization with live influenza vaccine

18. Other adverse events after immunization (fever above 40°C, syncope, non-febrile convulsions, anaphylaxis) when there is a minimal likelihood that they are associated with a previous administration of any vaccine

19. Suspicion of hypersensitivity to any component of the study vaccine, including egg protein

20. Acute or chronic clinically significant lung, cardiovascular, hepatic, endocrine, neurological, or psychiatric disorders, or impaired renal function identified by history, physical examination, or clinical laboratory findings that, in the opinion of the investigator, may influence the outcome of the study

21. History of oncological diseases

22. History of thrombocytopenic purpura or bleeding disorders

23. History of convulsions

24. Chronic alcohol dependence or chronic use of illicit drugs, drug abuse

25. Claustrophobia and social phobia according to history and / or available medical records

26. Inability to read Russian; inability or unwillingness to understand the essence of the study

27. Military personnel undergoing military service on conscription

28. Special diet (eg, vegetarian, vegan, salt-restricted) or lifestyle (night work, extreme physical activity)

29. Any condition that, in the opinion of the investigator, may increase the risk to the health of a volunteer participating in the study or affect the results of the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Pavlov First Saint Petersburg State Medical University

OTHER

Sponsor Role: collaborator

St. Petersburg City Polyclinic No. 34

UNKNOWN

Sponsor Role: collaborator

Research Institute of Influenza, Russia

OTHER

Sponsor Role: lead

Responsible Party

Tatyana Zubkova

Head of the clinical department

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Marina Stukova, Dr

Role: STUDY_DIRECTOR

Smorodintsev Research Institute of Influenza

Locations

Pavlov First Saint Petersburg State Medical University

Saint Petersburg, , Russia

Smorodintsev Research Institute of Influenza

Saint Petersburg, , Russia

St. Petersburg City Polyclinic No. 34

Saint Petersburg, , Russia

Countries

Russia

Other Identifiers

ВПТ-2-06/2023

Identifier Type: -

Identifier Source: org_study_id